Virtual Surveillance Visits with Symptom, Serum CA-125 Review May Offer Alternative for Ovarian Cancer Recurrence Detection.February 1st 2022
In patients with ovarian cancer and pretreatment elevated CA-125 who achieved remission after frontline therapy, most recurrences are detected by rising CA-125 levels or symptoms.
Secondary Cytoreductive Surgery Requires Careful Selection in Recurrent Ovarian Cancer
Amer Karam, MD, discusses the role of secondary cytoreductive surgery in ovarian cancer and the need for careful patient selection, plus the results from 3 clinical trials and the key differences between these efforts.
Role of PARP Inhibition Shifts in Ovarian Cancer as Research Efforts ExpandFebruary 11th 2020
Robert L. Coleman, MD, FACOG, FACS, discusses the role of rucaparib as a treatment option for patients with ovarian cancer, how this agent compares with other PARP inhibitors in this space, and where research is headed for these agents.
Dr. Secord on Financial Toxicity Associated With PARP InhibitionFebruary 10th 2020
Angeles Alvarez Secord, MD, discusses a presentation from the 2020 SGO Winter Meeting that focused on assistance with the financial burden associated with PARP inhibitors in patients with ovarian cancer.
Targeted Therapy, Immunotherapy Are Replacing Chemotherapy in Endometrial CancerFebruary 8th 2020
Researchers and practicing physicians have done as much as possible with chemotherapy as a systemic treatment for endometrial cancers, and other modalities—alone and in combination—are likely to become standard of care in the coming years, Shannon N. Westin, MD, MPH, said during a presentation at the 2020 SGO Winter Meeting.
Expert: Frontline Maintenance With PARP Inhibition Should Be Standard in Ovarian CancerFebruary 7th 2020
Maintenance treatment with PARP inhibitors should be the standard of care in the frontline setting for patients with ovarian cancer, Kathleen M. Moore, MD, said during a presentation at the 2020 Society of Gynecologic Oncology Winter Meeting.